Agents expected to antagonise or downregulate BCL-2 or MCL-1.
收藏NIAID Data Ecosystem2026-03-10 收录
数据链接：
官方服务：
资源简介：
Agents expected to antagonise or downregulate BCL-2 or MCL-1.
应用场景：
创建时间：
2018-01-04
相关数据集
Supplementary Material:Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study
Supplementary Materials for the manuscript: Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-ins
Mendeley Data2024-01-31 更新90
Supplementary Material for: Paclitaxel/Ramucirumab vs. Paclitaxel in 2nd-line therapy of advanced esophageal squamous cell carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial
Introduction: In squamous cell carcinoma of the esophagus (ESCC), therapeutical options in 2nd-line treatment are scarce with immune checkpoint inhibition being the only approved one. Ramucirumab/pacl
DataCite Commons2025-05-01 更新80
Therapeutic role of memantine for the prevention of cognitive decline in cancer patients with brain metastasis receiving whole-brain radiotherapy: a narrative review
ABSTRACT. Brain metastases are the most common central nervous system tumors. The mainstay treatment for this tumor in low to middle income countries is whole brain radiation therapy. Irreversible cog
DataCite Commons2022-05-27 更新60
Recent advances in nano-molybdenum oxide for photothermal cancer therapy
Cancer remains a significant global health challenge, driving the search for innovative treatments. Photothermal therapy (PTT) has emerged as a promising approach, using photothermal agents to convert
DataCite Commons2025-04-08 更新80
Changes in health related factors after surgery and medical treatments by the survival stages among Korean female cancer patients.
Changes in health related factors after surgery and medical treatments by the survival stages among Korean female cancer patients.
NIAID Data Ecosystem60
